Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 10/20 | 0.56 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | DHODH | Q02127 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495250 | 0.86 | CD38 (0.60) | CD38WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL28723076 | 0.86 | CD38 (0.60) | CD38WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL29495257 | 0.81 | CD38 (0.41) | CD38DHODH | |
| SCHEMBL29495213 | 0.78 | CD38 (0.54) | CD38 | |
| SCHEMBL31266813 | 0.72 | DHODH (0.43) | DHODH | |
| SCHEMBL5188098 | 0.68 | AKR1C4 (0.42) | DYRK1ADHODHCYP19A1 | |
| SCHEMBL29495224 | 0.68 | CD38 (0.46) | CD38 | |
| SCHEMBL28722350 | 0.68 | CD38 (0.46) | CD38 | |
| SCHEMBL1784081 | 0.68 | ALDH1A1 (0.47) | CD38 | |
| SCHEMBL23304628 | 0.68 | CD38 (0.64) | CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |